OakChart

Eton Pharmaceuticals Inc

ETONHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 3:59 PM ET

68.40+0.86 (1.27%)
2026-11-12 02:47 CET
Market cap
1,948.00 USD m
Revenue, TTM
141.06 USD m
Net income, TTM
49.86 USD m
Free cash flow, TTM
38.22 USD m
EPS diluted, TTM
1.51
P/E
45.31
Compare

Price

ETON against its 20, 50 and 200-day averages
2050200beatmiss
20.0040.0060.001.2M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ETONclose 68.4020-day 53.2950-day 55.19200-day 37.3868.40

3.2% under the 52-week high of 70.64 on 11 Nov 2026. 52-week low 14.27 on 5 Feb 2026. Last 15 sessions, 50.2% high to low

Volume 1.88× normal · the line is the 50-bar volume average

Profile

ETON
52-week range, 100% of the way up
14.2768.38

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

IndexRUT
Employees44
IPONov 13, 2018
Beta0.80
ATR, 14d3.97
Rel volume1.88
Short float7.24%
Insider own4.93%
Inst own72.62%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.97B
Enterprise Value1.94B
Income49.86M
Sales141.06M
Book/sh3.02
Cash/sh1.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees44
IPONov 13, 2018

Ratios

P/E45.31
Forward P/E23.63
PEG0.19
P/S13.99
P/B22.68
P/C35.46
P/FCF51.62
EV/EBITDA42.51
EV/Sales13.76
Quick Ratio1.58
Current Ratio1.79
Debt/Eq0.28
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)1.51
EPS next Y2.90
EPS next Q0.53
EPS this Y474.29%
EPS next Y44.03%
EPS next 5Y125.39%
EPS past 3/5Y21.89% 33.66%
Sales past 3/5Y55.53% 359.57%
EPS Y/Y TTM806.82%
Sales Y/Y TTM100.61%
EPS Q/Q1580.03%
Sales Q/Q157.91%
EarningsNov 05 AMC
EPS/Sales Surpr.239.20% 37.97%

Ownership

Insider Own4.93%
Insider Trans-32.50%
Inst Own72.62%
Inst Trans10.41%
ROA38.10%
ROE90.62%
ROIC50.28%
Gross Margin69.15%
Oper. Margin28.85%
Profit Margin35.35%
SMA2028.36%
SMA5023.93%
SMA20082.98%
Trades-

Technical

Shs Outstand28.83M
Shs Float27.42M
Short Float7.24%
Short Ratio3.29
Short Interest1.99M
52W High68.38 0.03%
52W Low14.27 379.33%
Volatility10.63% 6.27%
ATR (14)3.97
RSI (14)73.32
Beta0.80
Rel Volume1.88
Avg Volume603.17K
Volume1,133,881

Performance

Perf Week34.86%
Perf Month28.26%
Perf Quarter67.65%
Perf Half Y121.93%
Perf YTD304.49%
Perf Year287.32%
Perf 3Y1681.25%
Perf 5Y1304.52%
Perf 10Y-
Recom1.00
Target Price80.75
Prev Close67.54
Price68.40
Change %1.27%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jul 17, 2026InitiatedCCanaccord GenuityBuy$60-12.3%
Jan 23, 2025ReiteratedHH.C. WainwrightBuy$17 → $33-51.8%
Jan 10, 2025InitiatedRB. Riley SecuritiesBuy$21-69.3%
Jan 06, 2025ReiteratedHH.C. WainwrightBuy$15 → $17-75.1%
Sep 04, 2024ResumedHH.C. WainwrightBuy$9-86.8%
May 06, 2024InitiatedCCraig HallumBuy$8-88.3%
Oct 14, 2021ResumedRB. Riley SecuritiesBuy$10-85.4%
Jan 04, 2021ReiteratedHH.C. WainwrightBuy$20 → $15-78.1%
Sep 20, 2019InitiatedBB. Riley FBRBuy$13.50-80.3%
Jun 10, 2019InitiatedHH.C. WainwrightBuy$15-78.1%

Peers

Mkt cap
TickerCompanyMkt cap
XERSXeris Biopharma Holdings Inc3.02B
NBIXNeurocrine Biosciences Inc17.65B
ANIPANI Pharmaceuticals Inc1.63B
HROWHarrow Inc1.10B
ZVRAZevra Therapeutics Inc705.13M
TVTXTravere Therapeutics Inc5.00B
HRMYHarmony Biosciences Holdings Inc2.01B
ASNDAscendis Pharma A/S17.03B
RYTMRhythm Pharmaceuticals Inc7.78B
SPRBSpruce Biosciences Inc132.78M

Insider trading

latest 14 of 44
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
CASAMENTO CHARLES JDirectorNov 10 '26Option Exercise5.4480,555438,07780,555Nov 10 06:21 PM
CASAMENTO CHARLES JDirectorNov 10 '26Sale66.3580,5555,345,0720Nov 10 06:21 PM
Erdogan-Trinkaus IpekOfficerNov 10 '26Proposed Sale67.413,500235,937Nov 10 05:04 PM
CASAMENTO CHARLES JDirectorNov 10 '26Proposed Sale66.3180,5555,341,736Nov 10 04:53 PM
Krempa DavidChief Business OfficerOct 06 '26Sale55.074,166229,40643,381Oct 06 04:49 PM
Krempa DavidOfficerOct 06 '26Proposed Sale55.074,166229,406Oct 06 04:05 PM
MAIER PAUL VDirectorAug 28 '26Option Exercise3.7850,000189,000109,745Aug 28 04:51 PM
MAIER PAUL VDirectorAug 28 '26Sale59.0750,0002,953,57259,745Aug 28 04:51 PM
MAIER PAUL VDirectorAug 28 '26Proposed Sale59.0750,0002,953,530Aug 28 04:41 PM
Krempa DavidChief Business OfficerAug 24 '26Option Exercise7.3125,000182,75062,025Aug 24 05:19 PM
Krempa DavidChief Business OfficerAug 24 '26Sale65.0725,0001,626,75037,025Aug 24 05:19 PM
Krempa DavidOfficerAug 24 '26Proposed Sale65.0725,0001,626,750Aug 24 04:19 PM
BRYNJELSEN SEANPresident & CEOAug 20 '26Sale60.7091,0225,525,301961,194Aug 20 06:26 PM
BRYNJELSEN SEANPresident & CEOAug 19 '26Sale62.658,978562,4721,052,216Aug 20 06:26 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FYXFirst Trust Small Cap Core AlphaDEX FundAUM: 1.39B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Eton Pharmaceuticals Crushes Estimates And Raises Guidance Again, But A Tax Benefit Inflates The GAAP Beat (Earnings Whispers) -7.04% +19.75%
  • Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability (GlobeNewswire)
  • Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms (GlobeNewswire)
  • Eton's First Full Hemangiol Quarter Tests Whether A $145 Million Guide Was Conservative (Earnings Whispers)
  • Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 (GlobeNewswire)
  • Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT (diazepam) Buccal Film (GlobeNewswire)
  • Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (miltefosine) Capsules (GlobeNewswire)
  • Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference (GlobeNewswire)
  • Three Biotech Stocks Stick Out With Their Stellar Charts (Investor's Business Daily) +5.94%
  • This Analyst Believes Eton Pharmas Raised Guidance Is Conservative ETON Stock Heads For Best Ever Day (Stocktwits) +44.26%
  • Eton Pharmaceuticals Inc (ETON) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
  • Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-051.0600.3131.06057.9341.984
2026Q22026-08-130.3500.1900.35337.5927.112
2026Q12026-05-140.1400.1130.04924.2722.313
2025Q42026-03-190.0900.1330.04820.6619.983
2025Q32025-11-060.0400.090-0.07222.4620.463
2025Q22025-08-07-0.100-0.037-0.09618.9316.713
2025Q12025-05-13-0.0600.053-0.05917.2815.143
2024Q42025-03-18-0.020-0.003-0.02311.6510.533
2024Q32024-11-120.020-0.0100.02410.329.702
2024Q22024-08-08-0.120-0.070-0.1189.078.801
2024Q12024-05-09-0.030-0.070-0.0327.977.701
2023Q42024-03-14-0.090-0.040-0.0887.317.701
2023Q32023-11-09-0.020-0.100-0.0237.036.261
2023Q22023-08-100.180-0.0900.17612.006.501
2023Q12023-05-11-0.100-0.140-0.1045.304.601
2022Q42023-03-160.0400.0100.0368.509.101

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.030-1.147-1.0320.961.17
2020FY-1.330-1.275-1.3310.041.16
2021FY-0.080-0.080-0.07821.8323.30
2022FY-0.360-0.380-0.35921.2521.80
2023FY-0.0400.010-0.03731.6432.00
2024FY-0.150-0.127-0.14839.0137.91
2025FY0.3500.370-0.15076.2379.27
2026FY-2.010--179.9
2027FY-2.895--286.9
2028FY-4.008--356.33
2029FY-5.637--454.02
2030FY-6.957--530.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0644060.1658.4062.20
2026Q4S2026-11-0540045.8644.3947.50
2026Q4S2026-10-2840045.8644.3947.50
2026Q4S2026-08-1444045.8644.3947.50
2026Q4S2026-08-1041038.1735.3040.60
2026Q4S2026-07-2941038.1835.3340.60
2026Q4S2026-07-2743038.1835.3340.60
2026Q4S2026-07-1542037.9335.3340.60
2026Q4S2026-05-2033037.8735.3340.60
2026Q4S2026-05-1533037.8735.3340.60
2026Q4S2026-05-0132035.9432.5037.70
2026Q4S2026-03-2032034.0131.9037.63
2026Q4S2026-03-0222029.4528.6030.30
2026Q4S2026-02-2721028.0527.5128.60

Estimate history

EPS, annual-0.491-5.801-1.032-1.331-0.078-0.359-0.037-0.148-0.1711.5095
Period201720182019202020212022202320242025TTM
EPS, quarterly0.024-0.023-0.059-0.096-0.0720.0480.0490.3531.06
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000.9590.03921.83221.25131.64239.01179.95141.06
Period201720182019202020212022202320242025TTM
Sales, quarterly10.32411.64717.28218.92822.45921.28124.26637.58957.925
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.60817.60817.87724.31324.62625.35325.68826.70927.04728.828
Period201720182019202020212022202320242025MRQ
Shares, quarterly25.83626.70926.81826.81826.81827.04727.3628.2928.828
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue141.0679.9539.0131.6421.2521.830.040.960.00
Cost of Goods Sold Incl. D&A43.5137.2115.6010.586.932.620.940.450.06
Gross Profit97.5542.7423.4121.0614.3219.21-0.900.51-0.06
Selling, General and Administrative Excl. Other56.8642.6725.5922.2522.5820.7026.2119.1110.26
Research and Development9.927.763.253.324.006.2414.1011.555.63
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income40.690.07-2.18-1.19-8.26-1.50-27.11-18.60-10.32
Interest Expense5.664.782.001.060.951.040.89-0.00
Unusual Expense0.010.920.410.000.00-0.360.00-2.58
Net Income Before Taxes37.06-4.56-3.81-0.69-9.02-1.96-27.97-18.32-12.74
Income Taxes-12.800.040.010.250.000.000.000.000.00
Consolidated Net Income49.86-4.60-3.82-0.94-9.02-1.96-27.97-18.32-12.74
Net Income From Continuing Operations49.86-4.60-3.82-0.94-9.02-1.96-27.97-18.32-12.74
Net Income49.86-4.60-3.82-0.94-9.02-1.96-27.97-18.32-37.23
EPS (Recurring)1.50-0.15-0.14-0.04-0.36-0.09-1.33-1.03-5.52
EPS (Basic, Before Extraordinaries)1.76-0.17-0.15-0.04-0.36-0.08-1.33-1.03-5.80
EPS (Diluted)1.51-0.17-0.15-0.04-0.36-0.08-1.33-1.03-5.80
EBITDA45.674.12-1.04-0.29-6.50-1.05-26.46-18.15-10.26
Non-Operating Income (Expense)2.041.070.791.560.190.220.030.280.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.864.352.502.484.223.382.581.891.85
Price To Earnings Ratio44.7444.74-51.71-----
Price To Sales Ratio12.145.698.843.553.344.954,379.78133.35-
Gross Margin69.1553.4660.0166.5667.3887.99-2,302.5652.76-
Operating Margin28.850.09-5.59-3.77-38.87-6.85-69,515.38-1,939.62-
Net Margin35.35-5.75-9.80-2.96-42.45-8.95-71,717.95-1,910.32-
Shares Outstanding28.8327.0526.7125.6925.3524.6324.3117.8817.61
Market Capitalization1,948.001,948.00354.78112.3871.34105.56196.86128.21107.76

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue57.9237.5924.2721.2822.4618.9317.2811.65
Cost of Goods Sold Incl. D&A13.6212.189.538.1814.607.007.425.17
Gross Profit44.3025.4114.7313.107.8611.929.866.48
Selling, General and Administrative Excl. Other21.2912.6212.3210.639.0313.349.685.85
Research and Development5.270.991.881.781.113.711.16-0.87
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income23.0112.792.412.47-1.17-1.410.180.63
Interest Expense0.962.361.141.211.211.201.161.33
Unusual Expense0.000.000.000.010.190.060.660.00
Net Income Before Taxes22.3611.721.571.41-1.96-2.52-1.50-0.51
Income Taxes-12.890.140.02-0.07-0.030.070.070.09
Consolidated Net Income35.2511.581.551.48-1.93-2.58-1.57-0.60
Net Income From Continuing Operations35.2511.581.551.48-1.93-2.58-1.57-0.60
Net Income35.2511.581.551.48-1.93-2.58-1.57-0.60
EPS (Recurring)1.060.350.050.05-0.07-0.09-0.04-0.02
EPS (Basic, Before Extraordinaries)1.230.420.060.06-0.07-0.10-0.06-0.02
EPS (Diluted)1.060.350.050.05-0.07-0.10-0.06-0.02
EBITDA24.4614.183.543.49-0.16-0.411.200.98
Non-Operating Income (Expense)0.301.280.300.160.620.150.140.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.611.161.200.890.861.660.950.62
Price To Earnings Ratio44.74-------
Price To Sales Ratio12.1411.248.966.618.316.597.228.92
Gross Margin76.4867.6160.7261.5634.9763.0057.0655.60
Operating Margin39.7334.049.9511.61-5.22-7.451.075.40
Net Margin60.8530.806.406.97-8.58-13.66-9.10-5.13
Shares Outstanding28.8328.2927.3627.0526.8226.8226.8226.71
Market Capitalization1,948.00991.60673.38453.48582.74382.15348.09354.78

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments25.9414.9421.3916.3014.4121.3012.0726.7313.16
Short Term Receivables11.765.363.411.855.470.050.470.000.00
Inventories15.4215.230.910.560.551.240.380.000.00
Other Current Assets7.465.491.131.293.182.122.090.770.14
Total Current Assets60.5841.0226.8420.0023.6024.7015.0127.5013.29
Net Property, Plant & Equipment0.640.210.150.260.221.001.280.770.12
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets30.8834.884.744.753.620.570.72--
Other Assets0.020.010.010.010.020.040.060.050.03
Total Assets92.1176.1231.7425.0327.4626.3217.0728.3313.44
Short Term Debt Incl. Current Port. of LT Debt8.850.085.431.111.500.280.130.000.00
Accounts Payable10.984.171.851.771.772.340.571.420.54
Other Current Liabilities18.6615.708.963.591.281.171.250.600.25
Total Current Liabilities38.4919.9516.246.464.563.791.962.020.79
Long Term Debt22.2329.920.025.495.286.864.560.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities5.241.830.000.000.000.000.000.000.52
Total Liabilities65.9651.7016.2611.959.8410.666.522.021.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0019.00
Common Equity26.1524.4315.4813.0817.6315.6610.5526.30-6.87
Total Shareholders Equity26.1524.4315.4813.0817.6315.6610.5526.3012.13
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity26.1524.4315.4813.0817.6315.6610.5526.3012.13
Total Liabilities & Stockholders Equity92.1176.1231.7425.0327.4626.3217.0728.3313.44
Book Value Per Share0.970.910.600.520.720.640.591.49-0.39
Tangible Book Value Per Share-0.17-0.390.420.330.570.620.551.49-0.39
Full-Time Employees44313028171617159
Price to Book Ratio22.4021.536.656.385.9912.6212.204.10-6.44
Return on Assets-5.47-7.09-3.30-34.37-7.27-128.92-80.71-61.00-
Return on Equity-18.19-19.16-6.56-58.75-11.74-213.41-99.42-66.30-
Return on Invested Capital-9.51-7.03-6.04-48.58-8.53-124.17-121.25-48.44-58.99
Quick Ratio1.171.291.603.015.066.187.4513.5916.76
Current Ratio1.572.061.653.105.186.517.6513.5916.76

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income49.86-4.60-3.82-0.94-27.06-1.96-27.97-18.32-12.74
Depreciation4.984.041.150.901.770.460.650.450.06
Other Funds (Non Cash)2.4011.944.343.2522.392.983.961.904.43
Funds from Operations57.2411.381.673.22-2.901.49-23.36-15.97-8.24
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-18.89-0.86-0.703.607.72-6.211.01-2.060.10
Cash from Operating Activities38.3510.520.976.824.82-4.72-22.35-18.03-8.14
Capital Expenditures-18.36-0.33-10.01-0.78-2.79-3.26-0.05-1.85-0.24
Net Assets From Acquisitions0.000.00-30.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.700.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-18.36-0.33-40.01-0.78-2.79-2.56-0.05-1.85-0.24
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.300.608.190.200.250.5429.150.4521.96
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.300.608.190.200.250.5429.150.4521.96
Proceedsfrom Stock Options0.000.007.000.000.000.0028.780.0021.96
Issuance or Reduction of Debt, Net-8.000.0024.15-1.16-0.39-0.152.484.750.00
Change in Long Term Debt-8.000.0024.15-1.16-0.39-0.152.484.750.00
Issuance of Long Term Debt0.000.0025.310.000.000.002.484.750.00
Reduction of Long Term Debt-8.000.00-1.16-1.16-0.39-0.150.000.000.00
Net Financing Active Other Cash Flow0.220.220.250.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-1.490.8132.59-0.96-0.130.3931.625.2021.96
Net Change in Cash18.5111.01-6.455.081.90-6.899.23-14.6713.58
Free Cash Flow38.2210.190.946.824.78-4.73-22.40-19.12-8.38
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow44.8244.65365.7716.4814.83----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments55.6326.8419.6625.9437.1225.38
Short Term Receivables26.4324.8913.4111.7613.0814.45
Inventories11.0810.1414.4715.4216.8623.79
Other Current Assets3.656.725.717.464.944.82
Total Current Assets96.7868.6053.2460.5872.0068.44
Net Property, Plant & Equipment1.401.470.670.640.610.34
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets44.2845.6843.7430.8831.8832.88
Deferred Tax Assets14.74-----
Other Assets0.060.060.050.020.020.01
Total Assets157.27115.8197.7192.11104.51101.68
Short Term Debt Incl. Current Port. of LT Debt12.099.0611.888.852.812.79
Accounts Payable16.5014.4013.4810.9814.2612.14
Income Tax Payable1.63-----
Other Current Liabilities23.8821.6618.8118.6627.1223.66
Total Current Liabilities54.0945.1244.1838.4944.1838.60
Long Term Debt12.2420.1619.3822.2328.0727.90
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities4.013.943.545.249.1311.22
Total Liabilities70.3569.2267.0965.9681.3877.72
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity86.9246.5930.6126.1523.1323.96
Total Shareholders Equity86.9246.5930.6126.1523.1323.96
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity86.9246.5930.6126.1523.1323.96
Total Liabilities & Stockholders Equity157.27115.8197.7192.11104.51101.68
Book Value Per Share3.021.651.120.970.860.89
Tangible Book Value Per Share1.480.03-0.48-0.17-0.33-0.33
Full-Time Employees---44--
Price to Book Ratio22.4032.3525.5219.6124.3215.63
Return on Assets38.1011.67-1.62-5.47-9.52-6.18
Return on Equity90.6235.97-5.36-18.19-34.17-22.06
Return on Invested Capital35.5517.353.113.07-3.76-4.98
Quick Ratio1.581.300.881.171.251.16
Current Ratio1.791.521.211.571.631.77

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income35.2511.581.551.48-1.93-2.58
Depreciation1.441.391.131.021.011.00
Other Funds (Non Cash)-5.812.662.233.322.603.36
Funds from Operations30.8815.624.915.821.681.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.36-8.372.49-17.3710.346.17
Cash from Operating Activities35.247.257.41-11.5512.037.96
Capital Expenditures-3.240.01-15.07-0.05-0.280.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-3.240.01-15.07-0.05-0.280.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.782.921.390.200.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.782.921.390.200.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-5.00-3.000.000.000.000.00
Change in Long Term Debt-5.00-3.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-5.00-3.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.220.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-3.22-0.081.390.420.000.00
Net Change in Cash28.787.18-6.28-11.1811.747.96
Free Cash Flow35.237.267.33-11.6011.747.96
Price to Free Cash Flow44.8280.5750.4651.8427.8131.35

Revenue breakdown

License2024: 500.00K 2025: 3.29M
Product Sales and Royalties2024: 38.51M 2025: 76.66M
United States2024: 39.01M 2025: 79.95M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.24%2.0M27.4M561.61K
2026-10-157.15%1.9M27.2M610.07K
2026-09-306.75%1.8M27.2M581.09K
2026-09-155.68%1.5M27.2M558.01K
2026-08-314.97%1.3M27.1M539.91K
2026-08-145.26%1.4M27.1M502.03K
2026-07-315.07%1.3M25.9M475.48K
2026-07-154.73%1.2M25.9M412.41K
2026-06-305.54%1.4M26.2M420.54K
2026-06-155.45%1.4M26.2M425.86K
2026-05-294.82%1.3M26.2M415.76K
2026-05-155.95%1.5M26.0M403.49K
2026-04-307.06%1.6M23.2M367.66K
2026-04-157.74%1.8M23.2M349.32K
2026-03-318.20%1.9M23.1M321.38K
2026-03-138.21%1.9M23.1M254.90K
2026-02-279.76%2.2M22.7M251.35K
2026-02-139.28%2.1M22.7M242.01K
2026-01-308.79%2.0M22.7M256.29K
2026-01-158.89%2.0M22.8M258.02K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5063.8068.0029.2526.5430.000.000.999-0.0220.000
call5.0061.6065.5023.5915.8570.000.000.998-0.0230.001
call7.5059.6063.000.0012.5670.000.000.994-0.0820.002
call10.0057.1060.500.0010.6370.000.000.992-0.0840.002
call12.5054.6058.0026.049.2870.000.000.971-0.3700.007
call15.0051.6055.5016.058.2552.000.000.966-0.3780.008
call17.5049.6053.0039.947.5325.000.000.961-0.3830.009
call20.0046.6050.5043.156.8255.000.000.955-0.3850.010
call22.5044.6048.0039.806.1275.000.000.950-0.3860.011
call25.0042.1045.5030.105.60246.000.000.944-0.3840.012
call30.0037.9039.0024.803.36868.000.000.932-0.3780.014
call35.0032.1035.5021.003.9711210.000.918-0.3680.016
call40.0027.3030.4019.253.33313.000.000.902-0.3540.018
call45.0022.3025.5020.002.76739.000.000.882-0.3360.021
call50.0017.3020.5017.402.2531,0420.000.857-0.3140.024
call55.0012.3015.5013.501.8108822.000.822-0.2860.028
call60.007.609.509.250.98035627.000.769-0.2520.032
call65.003.806.503.601.10440.002.000.649-0.2580.039
call70.000.603.502.000.98468.006.000.472-0.2360.042
call75.000.052.000.751.02222.001.000.311-0.2200.038
call80.000.002.300.151.3322.000.000.259-0.2610.034
call85.000.002.250.101.5983.000.000.228-0.2920.032
call90.000.002.350.251.56711.000.000.159-0.2290.026
put2.500.000.050.008.6310.000.00-0.001-0.0190.000
put5.000.000.250.007.0350.000.00-0.002-0.0230.001
put7.500.000.250.007.0480.000.00-0.007-0.0730.002
put10.000.002.150.006.4440.000.00-0.008-0.0830.002
put12.500.002.150.009.3050.000.00-0.029-0.3680.007
put15.000.002.100.127.82351.000.00-0.032-0.3350.008
put17.500.002.102.257.0782.000.00-0.036-0.3400.009
put20.000.002.100.576.4151.000.00-0.041-0.3410.009
put22.500.002.150.135.85412.000.00-0.045-0.3400.010
put25.000.002.104.005.32060.000.00-0.051-0.3370.011
put30.000.002.150.504.4730.000.00-0.063-0.3310.013
put35.000.002.101.153.9932110.00-0.082-0.3640.016
put40.000.002.100.303.3541530.00-0.098-0.3490.018
put45.000.002.100.052.7882622.00-0.118-0.3310.021
put50.000.002.100.472.27449.000.00-0.143-0.3080.024
put55.000.002.100.501.79418.000.00-0.178-0.2800.028
put60.000.002.152.101.34716.000.00-0.231-0.2450.032
put65.000.003.201.301.1457.003.00-0.351-0.2500.039
put70.002.554.900.000.9530.000.00-0.528-0.2280.042
put75.005.308.900.001.1200.000.00-0.689-0.2120.038
put80.009.9012.800.001.1110.000.00-0.741-0.2520.034
put85.0014.8017.8029.501.3601.000.00-0.772-0.2830.032
put90.0019.7023.0020.001.6561.001.00-0.841-0.2190.026

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-10SEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-08-314/A2026-08-28SEC
2026-08-28144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-20144/ASEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-123Initial statement of beneficial ownership of securities2026-07-31SEC
2026-08-058-KCurrent report2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11005.35M1
2026-1000229.41K1
2026-090000
2026-080010.67M4
2026-07005.83M4
2026-06001.62M1
2026-05007.06M4
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Opaleye Management Inc.10.44%
Nantahala Capital Management, LLC8.59%
EcoR1 Capital, LLC7.93%
BlackRock, Inc.6.92%
VANGUARD CAPITAL MANAGEMENT LLC3.57%
FMR LLC2.88%
MORGAN STANLEY2.80%
GEODE CAPITAL MANAGEMENT, LLC2.67%
STATE STREET CORP2.56%
OBERWEIS ASSET MANAGEMENT INC/1.83%

Funds

Fund% owned
iShares Russell 2000 ETF2.53%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.50%
Oberweis Micro-Cap Fund1.77%
Fidelity Small Cap Index Fund1.07%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Nuveen Quant Small Cap Equity Fund0.93%
Fidelity Small Cap Growth Fund0.92%
iShares Russell 2000 Growth ETF0.90%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.56%
Wasatch Micro Cap Fund0.55%

OakChart. ETON. Cached 15 minutes.